Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy

Research output: Contribution to journalArticle

Abstract

Summary This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival after high-dose chemotherapy (HDC). Twenty-four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58% and positive in 42% of patients. Ninety per cent of patients (9/10) with positive PET2 relapsed after HDC while all but one patient with negative PET2 maintained a complete remission. The 2-year progression-free survival was 93% vs. 10% for patients with negative and positive PET2, respectively (P <0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients.

Original languageEnglish
Pages (from-to)369-372
Number of pages4
JournalBritish Journal of Haematology
Volume145
Issue number3
DOIs
Publication statusPublished - May 2009

Fingerprint

Fluorodeoxyglucose F18
Hodgkin Disease
Positron-Emission Tomography
Drug Therapy
Fluorine
Deoxyglucose
Disease-Free Survival
Retrospective Studies
Survival

Keywords

  • Haemopoietic stem cell transplantation
  • Hodgkin lymphoma
  • Positron emission tomography

ASJC Scopus subject areas

  • Hematology

Cite this

@article{a3235a19b25943a3b546396dd62f465b,
title = "Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy",
abstract = "Summary This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival after high-dose chemotherapy (HDC). Twenty-four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58{\%} and positive in 42{\%} of patients. Ninety per cent of patients (9/10) with positive PET2 relapsed after HDC while all but one patient with negative PET2 maintained a complete remission. The 2-year progression-free survival was 93{\%} vs. 10{\%} for patients with negative and positive PET2, respectively (P <0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients.",
keywords = "Haemopoietic stem cell transplantation, Hodgkin lymphoma, Positron emission tomography",
author = "Luca Castagna and Stefania Bramanti and Monica Balzarotti and Barbara Sarina and Elisabetta Todisco and Antonella Anastasia and Massimo Magagnoli and Rita Mazza and Andrea Nozza and Laura Giordano and Marcello Rodari and Eva Rinifilo and Arturo Chiti and Armando Santoro",
year = "2009",
month = "5",
doi = "10.1111/j.1365-2141.2009.07645.x",
language = "English",
volume = "145",
pages = "369--372",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy

AU - Castagna, Luca

AU - Bramanti, Stefania

AU - Balzarotti, Monica

AU - Sarina, Barbara

AU - Todisco, Elisabetta

AU - Anastasia, Antonella

AU - Magagnoli, Massimo

AU - Mazza, Rita

AU - Nozza, Andrea

AU - Giordano, Laura

AU - Rodari, Marcello

AU - Rinifilo, Eva

AU - Chiti, Arturo

AU - Santoro, Armando

PY - 2009/5

Y1 - 2009/5

N2 - Summary This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival after high-dose chemotherapy (HDC). Twenty-four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58% and positive in 42% of patients. Ninety per cent of patients (9/10) with positive PET2 relapsed after HDC while all but one patient with negative PET2 maintained a complete remission. The 2-year progression-free survival was 93% vs. 10% for patients with negative and positive PET2, respectively (P <0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients.

AB - Summary This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival after high-dose chemotherapy (HDC). Twenty-four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58% and positive in 42% of patients. Ninety per cent of patients (9/10) with positive PET2 relapsed after HDC while all but one patient with negative PET2 maintained a complete remission. The 2-year progression-free survival was 93% vs. 10% for patients with negative and positive PET2, respectively (P <0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients.

KW - Haemopoietic stem cell transplantation

KW - Hodgkin lymphoma

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=64149094098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64149094098&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07645.x

DO - 10.1111/j.1365-2141.2009.07645.x

M3 - Article

C2 - 19344403

AN - SCOPUS:64149094098

VL - 145

SP - 369

EP - 372

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -